Create Well being Ventures, which is able to give attention to investing in payer- and pharma-facing early-stage digital well being firms with founders with expertise within the healthcare business, introduced its launch after closing its first fund of $21 million.
The VC agency will spend money on startups providing B2B platforms targeted on payers and pharmaceutical firms that purpose to enhance affected person engagement and the affected person care journey, together with medical trial recruitment and retention.
“We’ve heard firsthand from payers, suppliers and pharmaceutical firms that their enterprise targets are to raise the affected person expertise, facilitate higher well being outcomes and enhance entry to take care of all, particularly these with well being disparities,” Emma Cartmell, cofounder and managing companion of Create Well being Ventures, stated in an announcement.
“We all know that founders from the healthcare business intimately perceive easy methods to meet these challenges leveraging know-how, and supporting them is probably the most highly effective method that we are able to make investments and, in flip, positively impression the healthcare business.”
THE LARGER TREND
Different enterprise companies which have emerged up to now 12 months targeted on funding digital well being firms embody Amboy Avenue Ventures, which launched in 2023 after closing a $20 million fund to spend money on ladies’s well being and sexual wellness.
Earlier this 12 months, well being tech investor and Transcarent CEO Glen Tullman launched a brand new $100 million enterprise fund known as 62 Ventures. The brand new fund will spend money on startups outdoors his current fund 7wireVentures’ strict digital well being focus.
62 Ventures will give attention to schooling, well being and care environmental sustainability, in addition to different industries.
Final 12 months, Tullman’s 7wireVentures launched its largest fund thus far, closing a $217 million fund, bringing its property below administration to $500 million.
The agency stated one-third of the funding would go towards Collection B and Collection C funding that weren’t already part of the VC agency’s portfolio.
